**AUB KQ1 Evidence Table (Reference ID #76)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Karakus et al., 2009  **Country:**  Turkey  **Enrollment** **period:**  August 2004 to April 2005  **Intervention** **setting:**  Outpatient clinic  **Funding:**  NR  **Author industry relationship disclosures:**  NR  **Study Design:**  RCT  **Blinding:**  None | **Intervention:**  Vaginal micronized progesterone (8% gel) 90 mg, every other evening from menstrual cycle day 17 to 27  **Comparator:**  Dydrogesterone 10 mg orally twice daily for 10 days starting on cycle day 15  **Groups:**  **G1:** Vaginal progesterone  **G2:** Oral progesterone  **Followup:**  3 cycles | **Inclusion criteria:**   * Aged 35 to 45 years * No menopausal symptoms * Did not take hormone therapy * Diagnosed with dysfunctional uterine bleeding * No contraindication for progesterone or progestins * Endometrial thickness >5 mm by transvaginal ultrasound   **Exclusion criteria:**  Taking anticoagulants or antiprostaglandins  Prefer hormonal contraceptive methods  Known intolerance to progesterone or progestins  **N at enrollment:**  **G1:** 34  **G2:** 35  **N at followup:**  **G1:** 27  **G2:** 27  **Age, mean years ± SD:**  **G1:** 39.1 ± 3.6  **G2:** 39.6 ± 3.0  **BMI, mean kg/m2 ± SD:**  **G1:** 29.2 ± 5.4  **G2:** 30.3 ± 3.7  **G1 vs. G2:** p=0.371  **Gravidity, mean ± SD:**  **G1:** 4.4 ± 2.1  **G2:** 4.8 ± 2.3  **G1 vs. G2:** p=0.584  **Parity, mean ± SD:**  **G1:** 3.0 ± 1.4  **G2:** 3.6 ± 2.2  **G1 vs. G2:** p=0.209  **Race/ethnicity:**  NR | Secretory endometrium in endometrial sample, n (%):  **G1:** 8 (29.6)  **G2:** 6 (22.2)  **G1 vs. G2:** p=0.412 | **Bleeding:**  Irregular bleeding pattern,a n (%):  First cycle:  **G1:** 2 (7.4)  **G2:** 5 (18.5)  **G1 vs. G2:** p=0.42  Second cycle:  **G1:** 3 (11.1)  **G2:** 3 (11.1)  **G1 vs. G2:** p=1.0  Third cycle:  **G1:** 2 (7.4)  **G2:** 4 (14.8)  **G1 vs. G2:** p=0.67  Secretory endometrium in endometrial sample, n (%):  **G1:** 24 (88.9)  **G2:** 22 (81.5)  **G1 vs. G2:** p=0.732  **Quality of life:**  NR  **Pain:**  NR  **Sexual function:**  NR  **Patient satisfaction:**  Self-reported patient satisfaction with treatment, n (%):  **G1:** 23 (85)  **G2:** 21 (78)  **G1 vs. G2:** p=0.491  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions:**  See comment**b**  **Adverse events, n:**  Groin pain:  **G1:** 1  **G2:** 0  5-kg weight gain:  **G1:** 1  **G2:** 0  Ovarian cyst:  **G2:** 1  **G2:** 0 | **Overall quality:**  Poor  **Risk of bias:**  Randomization:  Low  Allocation concealment:  High  Selective reporting:  Unclear  Blinding patients/personnel:  High  Blinding outcome assessment:  Unclear  Incomplete outcome reporting:  High  Other:  Unclear |

**Table Notes**: a Regular bleeding: cycle length less than 35 days and no intermenstrual bleeding; b Oral estrogen added for n=1 in G2 because of 45-day menstrual delay.